Tetrahydrocannabinol/cannabinol/cannabidiol
pharmaceutical compound
Tetrahydrocannabinol/cannabinol/cannabidiol (THC/CBN/CBD), sold under the brand name Zenivol and also known by its developmental code name ZTL-101, is a cannabinoid medication used for the treatment of insomnia. It is approved and marketed in Germany.
Medical uses
THC/CBN/CBD is indicated for the management of insomnia. Clinical trials have shown that it improves time to sleep, reduces nighttime awakenings, increases total sleep time, and enhances sleep quality and feeling refreshed after sleep.
Available forms
The drug is administered sublingually as a liquid using a syringe about 1 hour before bedtime. Each 0.5 mL dose contains 10 mg δ9-tetrahydrocannabinol (THC), 1 mg cannabinol (CBN), and 0.5 mg cannabidiol (CBD), corresponding to a 20:2:1 mg/mL ratio.
One or two doses are typically taken per night.
Adverse effects
Reported side effects are generally mild and resolve upon waking.
They include dry mouth, dizziness, headache, and "feeling abnormal".
Pharmacology
Pharmacokinetics
The pharmacokinetics of the formulation have been investigated and described in clinical studies.
The public source identifies “Tetrahydrocannabinol/cannabinol/cannabidiol” as pharmaceutical compound. This brief keeps that definition visible, then builds a research path around Tetrahydrocannabinol, cannabinol and cannabidiol.
Why this record matters
A short description can identify a subject without explaining its stakes. For “Tetrahydrocannabinol/cannabinol/cannabidiol”, the useful work is to connect “pharmaceutical compound” to the records capable of establishing context and consequence.
The citation trail is more important than the brevity of the summary: it shows where individual claims can be examined in context. The source revision retrieved here is dated Jun 2, 2026. The linked authority identifier is Q136505456. None of the 0 selected statements returned an explicit reference.
Overview language is designed for orientation and should not be treated as a substitute for the evidence cited beneath it. The lead is largely declarative, so disagreement and counter-evidence require a deliberate search beyond the opening account. Authority statements aid reconciliation but still require their own references, qualifiers and ranks to be checked.
How to read it
Use the entry as an orientation point, then follow its citations and revision history. Names, dates and institutional relationships should be checked against the original record.
- Subject orientation
- Search vocabulary
- Locating named sources
The closest primary source, responsible institution and strongest cited specialist reference.
Three-step research path
- Establish the record: confirm the title “Tetrahydrocannabinol/cannabinol/cannabidiol”, its source revision and the description used here.
- Expand the search: follow Tetrahydrocannabinol/cannabinol/cannabidiol primary sources, Tetrahydrocannabinol/cannabinol/cannabidiol archive and Tetrahydrocannabinol research across catalogues and specialist indexes.
- Test the account: compare the strongest cited source with the responsible institution’s current record and note any disagreement.
Questions for further research
- Which source most directly establishes the central claim about “Tetrahydrocannabinol/cannabinol/cannabidiol”?
- What terminology or title could unlock a more precise catalogue search?
- Which institution is responsible for the underlying evidence?
Search terms from this dossier
This entry incorporates text from “Tetrahydrocannabinol/cannabinol/cannabidiol” on English Wikipedia. Contributors are listed in the page history. Text is available under the Creative Commons Attribution-ShareAlike 4.0 License. Selected authority identifiers and statements are retrieved from Wikidata under CC0; their references and qualifiers remain part of the verification path.